NCT05112211 Multi-model Image of Doxycycline in TAO
| NCT ID | NCT05112211 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sun Yat-sen University |
| Condition | Thyroid Associated Ophthalmopathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2022-01-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2022-01-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the efficacy of doxycycline treating Thyroid Associated Ophthalmopathy by multi-modal image.
Eligibility Criteria
Inclusion Criteria: * Informed consent * Age 18-70 years old * Diagnosed with TAO Exclusion Criteria: * Sight-threatening TAO with dysthyroid optic neuropathy * Allergy of tetracycline * Have contraindications of MRI(metal pacemaker, fake teeth, foreign body and other materials which will disturb the examination)
Contact & Investigator
Dan Liang
PRINCIPAL INVESTIGATOR
Zhongshan Ophthalmic Center, Sun Yat-sen University
Frequently Asked Questions
Who can join the NCT05112211 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Thyroid Associated Ophthalmopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05112211 currently recruiting?
Yes, NCT05112211 is actively recruiting participants. Contact the research team at liangdan@gzzoc.com for enrollment information.
Where is the NCT05112211 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT05112211 clinical trial?
NCT05112211 is sponsored by Sun Yat-sen University. The principal investigator is Dan Liang at Zhongshan Ophthalmic Center, Sun Yat-sen University. The trial plans to enroll 20 participants.